Brief: Mira Pharmaceuticals Reports Positive PTSD Data For Ketamir-2 - SEC Filing
15/09/2025 22:17
Sept 15 (Reuters) - SEC FILING: MIRA PHARMACEUTICALS INC - REPORTS POSITIVE PTSD DATA FOR KETAMIR-2 - SEC FILING MIRA PHARMACEUTICALS INC - ANIMALS DOSED WITH KETAMIR-2 ONCE DAILY FOR FIVE DAYS - SEC FILING MIRA PHARMACEUTICALS - KETAMIR-2 IN PHASE 1 TRIAL FOR NEUROPATHIC PAIN, WHERE IT HAS DEMONSTRATED FAVORABLE SAFETY PROFILE TO DATE Source text: [ID:n0001493152-25-013459] Further company coverage: MIRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing